Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:3-Deoxyvitamin D3)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST001680 AN002740 Metabolome of NAFLD in high fat diet mouse model Liver Mouse Fatty liver disease Weill Cornell Medicine Abundance
ST001796 AN002917 Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib Mesenteric lymph Mus musculus Diabetes Monash Institute of Pharmaceutical Sciences height
ST000310 AN000490 TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) Blood Mouse Lupus University of Florida Peak area
ST000311 AN000495 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak area
ST002412 AN003931 Metabolic effects of the protein kinase R Macrophages Mouse Hudson peak height
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University peak height
ST000310 AN000492 TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) Blood Mouse Lupus University of Florida Peak height
ST000311 AN000497 TC and B6 untreated plasma in lupus-prone mice Blood Mouse Lupus University of Florida Peak height
ST000403 AN000642 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000414 AN000655 Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000539 AN000818 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University Peak height
ST001274 AN002115 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST001275 AN002116 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST001276 AN002117 Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001201 AN001998 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001204 AN002004 Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001547 AN002576 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University Peak intensity
ST002094 AN003421 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic raw intensity
ST000046 AN000076 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST000046 AN000077 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST000047 AN000080 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) Cerebrospinal fluid Human Alzheimers disease Mayo Clinic Raw MS Intensities
ST002309 AN003771 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University relative intensity
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University Signal Intensity
ST001304 AN002172 Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii Fibroblast cells Toxoplasma gondii Parasitic infection Monash University Signal Intensity
ST001315 AN002189 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University Signal Intensity
  logo